Literature DB >> 3599659

Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease.

A J Walle, G Y Wong, G K Clemons, J F Garcia, W Niedermayer.   

Abstract

Deficient erythropoietin (EP) production is thought to be a key factor in the pathogenesis of the anemia of end-stage renal disease. We describe the interrelationships between radioimmunoassayed plasma EP levels, reticulocyte counts corrected for anemia (CRC) and hematocrit (HCT) under challenge by hemorrhage, transfusions and hemodialysis in 32 chronically-hemodialyzed patients. Spontaneous hemorrhage resulted in a decrease in HCT (P = 0.001) and increases in both EP (P = 0.006) and CRC levels (P = 0.0065). Transfusions of two units of packed red cells into each of 16 patients suppressed EP (P = 0.0004) and CRC (P less than 0.0001) after about 28 and 42 hours, respectively. Repeat transfusions after one to 27 days resulted in similarly significant suppressions of both EP and CRC, except the CRC remained on higher levels for prolonged periods of times. Within a few hours after each transfusion of 2,3-diphosphoglycerate-poor red cells, both EP (P = 0.009) and CRC (P = 0.007) increased temporarily between one to 18 and three to 38 hours, respectively. Hemodialysis resulted in alkalinization (P = 0.008) of blood but not in changes of EP or CRC counts. The data show that, with the EP-HCT feedback loop persisting, increased endogenous hormone levels elicit erythropoietic responses, and that the regulation of EP levels may involve determinants such as oxy-deoxyhemoglobin interactions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3599659     DOI: 10.1038/ki.1987.129

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Changes in erythropoietin and haemoglobin concentrations in response to saturation diving.

Authors:  Dag Hofsø; Rune J Ulvik; Kåre Segadal; Arvid Hope; Einar Thorsen
Journal:  Eur J Appl Physiol       Date:  2005-07-08       Impact factor: 3.078

2.  Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.

Authors:  Wanja M Bernhardt; Michael S Wiesener; Paul Scigalla; James Chou; Roland E Schmieder; Volkmar Günzler; Kai-Uwe Eckardt
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

Review 3.  Erythropoiesis and erythropoietin levels in renal transplant recipients.

Authors:  M Wolff; W Jelkmann
Journal:  Klin Wochenschr       Date:  1991-01-22

4.  Timing and determinants of erythropoietin deficiency in chronic kidney disease.

Authors:  Lucile Mercadal; Marie Metzger; Nicole Casadevall; Jean Philippe Haymann; Alexandre Karras; Jean-Jacques Boffa; Martin Flamant; François Vrtovsnik; Bénédicte Stengel; Marc Froissart
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-17       Impact factor: 8.237

5.  L-arginine administration reverses anemia associated with renal disease.

Authors:  Takahisa Tarumoto; Shigehiko Imagawa; Makoto Kobayashi; Aki Hirayama; Keiya Ozawa; Toshiro Nagasawa
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 6.  HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.

Authors:  Patrick H Maxwell; Kai-Uwe Eckardt
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

7.  DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys.

Authors:  Yu-Ting Chang; Ching-Chin Yang; Szu-Yu Pan; Yu-Hsiang Chou; Fan-Chi Chang; Chun-Fu Lai; Ming-Hsuan Tsai; Huan-Lun Hsu; Ching-Hung Lin; Wen-Chih Chiang; Ming-Shiou Wu; Tzong-Shinn Chu; Yung-Ming Chen; Shuei-Liong Lin
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

8.  End-stage kidneys are capable of increased erythropoietin production.

Authors:  K Morris; M Coulthard
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

9.  Effect of periodic transfusion on erythropoietin concentration in end stage renal disease.

Authors:  S Y Hong; D H Yang
Journal:  Korean J Intern Med       Date:  1992-07       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.